Foghorn Therapeutics Inc.FHTXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank43
3Y CAGR-12.5%
5Y CAGR+52.0%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-12.5%/yr
vs +51.3%/yr prior
5Y CAGR
+52.0%/yr
Recent deceleration
Acceleration
-63.8pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
8.1x
Strong expansion
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$91.31M-27.1%
2024$125.28M-11.8%
2023$142.06M+4.2%
2022$136.37M+33.6%
2021$102.05M+807.5%
2020$11.25M-77.2%
2019$49.29M+89.2%
2018$26.05M-